IVF/ICSI Protocols in Poor Responders With Growth Hormone

Woman's Health University Hospital, Egypt287 enrolled

Overview

in this study, we are trying to monitor the effect of the addition of growth hormone on the different down regulation protocols ( long, short, antagonist and microflare). The outcome will be primarily assessed by the clinical pregnancy rates.

Poor responders undergoing IVF/ICSI cycles have emerged as a major problem. the need to find a proper stimulation protocol is a must. in this study we are trying to detect the best stimulation protocol ,in addition to growth hormone ,that can give the highest pregnancy rates in these patients.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

287

Conditions

Female Infertility Due to Diminished Ovarian Reserve

Interventions

Growth hormone (Norditropin, Novo nordisk)DRUG

Eligibility

Sex: FEMALEMin age: 20 YearsMax age: 45 Years

Medical Language ↔ Plain English

Inclusion Criteria: ESHRE consensus 2011,At least two of the following three features must be present: * Advanced maternal age (≥40 years) or any other risk factor for POR; * A previous POR (≤3 oocytes with a conventional stimulation protocol); * An abnormal ovarian reserve test (i.e. AFC \< 5-7 follicles or AMH \< 0.5 -1.1 ng/ml). Exclusion Criteria: * female patients with causes of infertility other than poor ovarian reserve * females suffering from congenital or acquired uterine anomalies * females with focal uterine lesions * females who had previous ovarian surgeries * females with history of previous exposure to radiotherapy , or chemotherapy * females refusing to get enrolled in the study

Locations (1)

private IVF medical center

Giza, Cairo Governorate, Egypt

Outcomes

Primary Outcomes

Numbers of oocytes retrieved and number of fertilized oocytes

Number of oocytes retrieved on the day of vaginal egg collection guided by trans vaginal ultrasound scan , 35 hours after hCG administration.

Time frame: 2 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.